Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 39.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,383,029 shares of the company’s stock after selling 1,538,213 shares during the quarter. Baillie Gifford & Co. owned approximately 1.74% of Vir Biotechnology worth $17,849,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its stake in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the period. Innealta Capital LLC purchased a new stake in Vir Biotechnology in the 2nd quarter valued at approximately $32,000. nVerses Capital LLC purchased a new stake in Vir Biotechnology in the 3rd quarter valued at approximately $56,000. Magnetar Financial LLC acquired a new position in Vir Biotechnology during the 2nd quarter worth approximately $95,000. Finally, Quest Partners LLC raised its stake in shares of Vir Biotechnology by 142.1% during the 2nd quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after buying an additional 7,452 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares of the company’s stock, valued at approximately $90,604.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 15,940 shares of company stock valued at $127,410 in the last ninety days. Corporate insiders own 15.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Monday, November 4th. Finally, Barclays decreased their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $9.25 on Wednesday. Vir Biotechnology, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $13.09. The business has a fifty day simple moving average of $7.92 and a 200-day simple moving average of $8.95.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business’s revenue was down 9.8% compared to the same quarter last year. During the same quarter last year, the business posted ($1.22) earnings per share. On average, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.86 EPS for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).